Phase II, randomized trial of preoperative epirubicin-paclitaxel +/− gefitinib with biomarker evaluation in operable breast cancer
Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Gordana Jovic(MRC Clinical Trials Unit at UCL), Rossana Berardi(Marche Polytechnic University), Alberto Bottini(University of Genoa), Giuseppe Luigi Banna(Ospedale Cannizzaro), C. Boni(Ospedale Santa Maria), Nicola Battelli(Ospedale di Macerata), Simona Giovannelli(University of Modena and Reggio Emilia), Giancarlo Bisagni, Guido Ficarra(University of Modena and Reggio Emilia), Nicola Cresti(Ospedale Santa Chiara), Claudia Andreetta(Ospedale Santa Maria della Misericordia di Udine), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Beatrice Di Blasio(University of Parma), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Armando Santoro(IRCCS Humanitas Research Hospital), Antonino Maiorana(University of Modena and Reggio Emilia), Andrea Michelotti(University of Pisa), Fabio Puglisi(University of Udine)
Cited by 21
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k